Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Suzhou Genhouse Bio / Equity Capital Markets

<ul>
<li>Suzhou Genhouse Bio, a China-based biotech, is looking to raise at least USD100m via a Hong Kong listing. Huatai is the sole sponsor.</li>
<li>In this note, we look at the company's one late-stage core product, GH21.</li>
<li>We also look at the company's pre-IPO investors and management team.</li>
</ul>


Suzhou Genhouse Bio, a China-based biotech, is looking to raise at least USD100m via a Hong Kong listing. Huatai is the sole sponsor.
In this note, we look at the company's one late-stage core product, GH21.
We also look at the company's pre-IPO investors and management team.


Suzhou Genhouse Bio (勤浩医药) Pre-IPO: Moderate Innovation, Capped by Combination Economics